HIV Vaccine Trial Volunteers Asked To Undergo Testing To Determine Whether They Are At Increased Risk Of HIV

Main Category: HIV / AIDS
Also Included In: Clinical Trials / Drug Trials;  Immune System / Vaccines
Article Date: 30 Oct 2007 - 11:00 PDT

email to a friend   printer friendly   opinions  

Researchers have asked more than 3,000 people who participated in a trial of Merck's experimental HIV vaccine that was halted last month to undergo additional testing to determine if they are at an increased risk of HIV, Reuters reports (Fox, Reuters, 10/25).

Merck last month announced that it had ended its Phase II trial, which began in late 2004 and involved 3,000 HIV-negative volunteers, after its experimental vaccine failed to prevent HIV infection in participants or prove effective in delaying the progression of the virus to AIDS. The trial was stopped by the Data and Safety Monitoring Board, an independent overseer. Some researchers have theorized that because HIV-positive people who have stronger CD4+ T-cell responses tend to fight the virus better, a vaccine that simulated a T-cell response might be able to control HIV/AIDS. The Merck vaccine was made from a weakened version of a common cold virus that served as a mode for providing three synthetically produced genes from HIV, known as gag, pol and nef (Kaiser Daily HIV/AIDS Report, 10/25).

Researchers said that they do not have enough information to determine whether the participants who received the vaccine are more susceptible to HIV but that initial information is worrisome. Officials from Merck and NIH's National Institute of Allergy and Infectious Diseases emphasized that the vaccine could not result in HIV infection because it contains three synthetically produced genes that have "no way" to "reconstitute an intact virus."

According to NIAID, which co-sponsored the trial, researchers are "analyzing available data to better understand if there may be an increased susceptibility to acquiring HIV infection among those volunteers who received the vaccine." Mark Feinberg, Merck's vice president for medical affairs and public health, in an e-mail said that researchers are analyzing a "tremendous amount of data."

Mitchell Warren of the AIDS Vaccine Advocacy Coalition, who was not involved in the study, said the global health community is "still trying to figure out what the data mean," adding that he hopes the investigation will not deter people from participating in future HIV vaccine trials. "How people understand this information is going to be critical for this research to continue," Warren said (Reuters, 10/25).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

• Additional
• References
• Citations